Kyntra Bio (LTS:0IL8) Cyclically Adjusted FCF per Share: $-31.73 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0IL8 Kyntra Bio Inc LTS:0IL8
34 GF Score
Price $7.85
GF Value $4.71
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Kyntra Bio Cyclically Adjusted FCF per Share?

Kyntra Bio LTS:0IL8 -2.49% 34 Cyclically Adjusted FCF per Share is $-31.73 as of Jun. 2026. GuruFocus rates LTS:0IL8 with a GF Score™ of 34/100 and a GF Value™ of $4.71 (Significantly Overvalued). The stock has 9 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Kyntra Bio's adjusted free cash flow per share for the three months ended in Jun. 2026 was $-0.986. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-31.73 for the trailing ten years ended in Jun. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-09-02), Kyntra Bio's current stock price is $7.8497. Kyntra Bio's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was $-31.73. Kyntra Bio's Cyclically Adjusted Price-to-FCF of today is .


Kyntra Bio  (LTS:0IL8) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Kyntra Bio Cyclically Adjusted FCF per Share Related Terms


Kyntra Bio Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Kyntra Bio's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kyntra Bio Cyclically Adjusted FCF per Share Chart

Kyntra Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -23.00 -27.92 -28.06

Kyntra Bio Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -39.59 -30.14 -28.06 -27.94 -31.73

LTS:0IL8 vs IGC, ATNM, NNVC: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Kyntra Bio's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kyntra Bio Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kyntra Bio's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Kyntra Bio's Cyclically Adjusted Price-to-FCF falls into.


LTS:0IL8
34GF Score
Kyntra Bio Inc LTS:0IL8
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kyntra Bio Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Kyntra Bio's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.986/333.9520*333.9520
=-0.986

Current CPI (Jun. 2026) = 333.9520.

Kyntra Bio Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 -0.737 241.428 -1.019
201612 -7.376 241.432 -10.203
201703 -10.844 243.801 -14.854
201706 -7.442 244.955 -10.146
201709 -7.185 246.819 -9.721
201712 -1.427 246.524 -1.933
201803 -10.196 249.554 -13.644
201806 -10.995 251.989 -14.571
201809 2.101 252.439 2.779
201812 -6.061 251.233 -8.057
201903 6.417 254.202 8.430
201906 -8.279 256.143 -10.794
201909 -8.418 256.759 -10.949
201912 -13.393 256.974 -17.405
202003 -16.986 258.115 -21.977
202006 41.626 257.797 53.923
202009 -0.472 260.280 -0.606
202012 -2.637 260.474 -3.381
202103 -12.405 264.877 -15.640
202106 -7.651 271.696 -9.404
202109 4.763 274.310 5.799
202112 -15.186 278.802 -18.190
202203 -12.121 287.504 -14.079
202206 -9.085 296.311 -10.239
202209 -14.062 296.808 -15.822
202212 -14.051 296.797 -15.810
202303 -26.975 301.836 -29.845
202306 -28.540 305.109 -31.238
202309 -21.685 307.789 -23.528
202312 -4.714 306.746 -5.132
202403 -14.983 312.332 -16.020
202406 -9.988 314.175 -10.617
202409 -2.103 315.301 -2.227
202412 -7.585 315.605 -8.026
202503 0.669 319.799 0.699
202506 3.134 322.561 3.245
202509 -0.459 324.800 -0.472
202512 -4.530 324.054 -4.668
202603 -3.431 330.213 -3.470
202606 -0.986 333.952 -0.986

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $-31.73 mean?
Kyntra Bio (LTS:0IL8) has a Cyclically Adjusted FCF per Share of $-31.73 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Kyntra Bio and its competitors.
Is Kyntra Bio's Cyclically Adjusted FCF per Share too high?
Kyntra Bio's current Cyclically Adjusted FCF per Share is $-31.73. Overall, Kyntra Bio has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kyntra Bio's Cyclically Adjusted FCF per Share compare to IGC and ATNM?
Kyntra Bio's Cyclically Adjusted FCF per Share of $-31.73 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Kyntra Bio and its competitors. Kyntra Bio's current Cyclically Adjusted FCF per Share is $-31.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyntra Bio stock overvalued right now?
Based on GuruFocus' analysis, Kyntra Bio (LTS:0IL8) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.71, compared to a current price of $7.85 — trading 66.7% above its estimated fair value. The current Cyclically Adjusted FCF per Share is $-31.73. Kyntra Bio's overall GF Score™ is 34/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Kyntra Bio (LTS:0IL8), the current Cyclically Adjusted FCF per Share is $-31.73 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kyntra Bio (LTS:0IL8) Overvalued in 2026?

Based on GuruFocus' analysis, Kyntra Bio stock appears to be overvalued. The current stock price of $7.85 is trading 66.7% above its estimated GF Value™ of $4.71. GuruFocus considers Kyntra Bio to be Significantly Overvalued.

Key valuation signals for LTS:0IL8:

  • Cyclically Adjusted FCF per Share: $-31.73
  • GF Value™: $4.71 vs. price of $7.85 (66.7% above fair value)
  • GF Score™: 34/100 with 9 warning signs

No single metric tells the full story. See the LTS:0IL8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Kyntra Bio Business Description

Address 350 Bay Street, Suite 100, No. 6009, San Francisco, CA, USA, 94133
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
34GF Score

Get the complete analysis for LTS:0IL8

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.85
Price
$4.71
GF Value